Covered recipient · General Payments record
UMA BORATE
Allopathic & Osteopathic Physicians Internal Medicine Hematology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$60,031.56
63 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $38,094.75 | 14 |
| Travel and Lodging | $20,320.66 | 20 |
| Food and Beverage | $1,572.15 | 28 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44.00 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $25,516.78 | 22 |
| Daiichi Sankyo Inc. | $8,165.02 | 12 |
| JAZZ PHARMACEUTICALS INC. | $6,499.55 | 2 |
| Incyte Corporation | $5,396.89 | 8 |
| ImmunoGen, Inc. | $3,428.92 | 5 |
| E.R. Squibb & Sons, L.L.C. | $3,407.22 | 5 |
| SERVIER PHARMACEUTICALS LLC | $3,400.00 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,025.00 | 1 |
| Astellas Pharma US Inc | $1,750.76 | 2 |
| Celgene Corporation | $172.15 | 3 |
| Genentech USA, Inc. | $144.27 | 1 |
| Gilead Sciences, Inc. | $125.00 | 1 |
Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
UMA BORATE
NPI 1619182946 · CMS profile ID 209173
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology
COLUMBUS, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619182946?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- UMA BORATE, NPI 1619182946, CMS profile ID 209173. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619182946?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). UMA BORATE, NPI 1619182946, CMS profile ID 209173. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619182946?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- UMA BORATE, NPI 1619182946, CMS profile ID 209173, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1619182946?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
63 matching records · $60,031.56 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–63 of 63.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $645.00 | 04/14/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006582177 | CMS |
| Astellas Pharma US Inc | $1,708.00 | 03/16/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033982661 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,025.00 | 03/09/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993424199 | CMS |
| Daiichi Sankyo Inc. | $51.01 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006598951 | CMS |
| Daiichi Sankyo Inc. | $28.19 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006599341 | CMS |
| Daiichi Sankyo Inc. | $28.19 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006599529 | CMS |
| Daiichi Sankyo Inc. | $33.56 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006599627 | CMS |
| Daiichi Sankyo Inc. | $472.88 | 02/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006601273 | CMS |
| Daiichi Sankyo Inc. | $216.54 | 02/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006598969 | CMS |
| Daiichi Sankyo Inc. | $162.63 | 02/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006599445 | CMS |
| AbbVie Inc. | $675.00 | 02/02/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996283273 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,038.00 | 01/30/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016057865 | CMS |
| AbbVie Inc. | $2,868.75 | 01/19/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996283271 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,000.00 | 1 |
| PY2025 | Principal investigator | $9,315,054.29 | 382 |
| PY2024 | Principal investigator | $4,670,258.91 | 33 |
| PY2023 | Recipient | $872.18 | 2 |
| PY2023 | Principal investigator | $4,282,737.08 | 31 |
| PY2022 | Recipient | $1,000.00 | 1 |
| PY2022 | Principal investigator | $1,997,046.18 | 57 |
| PY2021 | Recipient | $7,890.85 | 6 |
| PY2021 | Principal investigator | $253,142.70 | 37 |
| PY2020 | Recipient | $4,728.93 | 4 |
| PY2020 | Principal investigator | $1,295,851.56 | 137 |
| PY2019 | Principal investigator | $1,637,212.39 | 63 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
383 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Geron Corporation | $630.00 | 12/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238897186 |
| Principal investigator 1 | Geron Corporation | $750.00 | 12/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238897190 |
| Principal investigator 1 | Geron Corporation | $4,000.00 | 12/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238897192 |
| Principal investigator 1 | Geron Corporation | $750.00 | 12/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238897196 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $27,495.00 | 12/15/2025 | Non-covered Recipient Entity The Ohio State University The Ohio State University | FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC | No dispute reported | 06/30/2026 | 1226096386 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,380.00 | 12/15/2025 | Non-covered Recipient Entity The Ohio State University The Ohio State University | FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC | No dispute reported | 06/30/2026 | 1226096392 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $410.00 | 12/12/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375405 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,710.00 | 12/12/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17,790.00 | 12/12/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,010.00 | 12/12/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,000.00 | 12/12/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,503.00 | 12/12/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375415 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $98,640.00 | 12/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211420121 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,980.60 | 12/08/2025 | Non-covered Recipient Entity The Ohio State University The Ohio State University | FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC | No dispute reported | 06/30/2026 | 1226096371 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,831.82 | 12/08/2025 | Non-covered Recipient Entity The Ohio State University The Ohio State University | FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC | No dispute reported | 06/30/2026 | 1226096378 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $9,562.00 | 12/04/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176656956 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,200.00 | 12/04/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176656961 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $59,793.91 | 12/03/2025 | Non-covered Recipient Entity Ohio State University Resear Fo | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1235994990 |
| Principal investigator 1 | Incyte Corporation | $16,089.08 | 12/03/2025 | Non-covered Recipient Entity The Ohio State University | A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1240602586 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20.00 | 12/01/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY | Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria | No dispute reported | 06/30/2026 | 1190305193 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $85,610.00 | 11/11/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418671 |
| Principal investigator 1 | Astellas Pharma Global Development | $109.00 | 11/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186727 |
| Principal investigator 1 | Astellas Pharma Global Development | $285.00 | 11/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186729 |
| Principal investigator 1 | Astellas Pharma Global Development | $260.00 | 11/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186731 |
| Principal investigator 1 | Astellas Pharma Global Development | $260.00 | 11/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186733 |
| Principal investigator 1 | Astellas Pharma Global Development | $260.00 | 11/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186735 |
| Principal investigator 1 | Astellas Pharma Global Development | $109.00 | 11/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186737 |
| Principal investigator 1 | Incyte Corporation | $72,400.88 | 11/04/2025 | Non-covered Recipient Entity The Ohio State University | A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1240602582 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $9,500.00 | 10/29/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415860 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,600.00 | 10/29/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415862 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $47,162.78 | 10/28/2025 | Non-covered Recipient Entity The Ohio State University | A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1233745004 |
| Principal investigator 1 | Geron Corporation | $4,000.00 | 10/27/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896365 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $360.00 | 10/27/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY CLINICAL TRIALS OFFICE | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176651674 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $157.51 | 10/23/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176651462 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186739 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186741 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186743 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,829.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186745 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186747 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186749 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186751 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186753 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186755 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186757 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186759 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186761 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186763 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186765 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186767 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186769 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186771 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186773 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186775 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186777 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186779 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186781 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186783 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186785 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186787 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186789 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186791 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186793 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186795 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186797 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186799 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186801 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,829.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186803 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186805 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186807 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186809 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186811 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186813 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186815 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186817 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186819 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186821 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186823 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186825 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186827 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186829 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186831 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186833 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186835 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186837 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186839 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186841 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186843 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186845 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186847 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 10/22/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186849 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $5,960.00 | 10/17/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417961 |
| Principal investigator 1 | Geron Corporation | $1,081.51 | 10/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896222 |
| Principal investigator 1 | Geron Corporation | $1,081.51 | 10/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896226 |
| Principal investigator 1 | Geron Corporation | $1,081.51 | 10/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896230 |
| Principal investigator 1 | Geron Corporation | $1,081.51 | 10/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896233 |
| Principal investigator 1 | Geron Corporation | $1,081.51 | 10/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896237 |
| Principal investigator 1 | Geron Corporation | $1,081.51 | 10/15/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238896242 |
| Principal investigator 1 | ABBVIE INC. | $832.64 | 10/14/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202516767 |
| Principal investigator 1 | ABBVIE INC. | $2,082.88 | 10/14/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202516769 |
| Principal investigator 1 | ABBVIE INC. | $8,329.60 | 10/14/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202516771 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 10/08/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) | No dispute reported | 06/30/2026 | 1223262740 |
| Principal investigator 1 | Servier BioInnovation | $17,800.00 | 10/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) | No dispute reported | 06/30/2026 | 1235975075 |
| Principal investigator 1 | Servier BioInnovation | $5,000.00 | 10/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) | No dispute reported | 06/30/2026 | 1235975078 |
| Principal investigator 1 | Servier BioInnovation | $6,000.00 | 10/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) | No dispute reported | 06/30/2026 | 1235975082 |
| Principal investigator 1 | Servier BioInnovation | $4,060.00 | 10/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) | No dispute reported | 06/30/2026 | 1235975086 |
| Principal investigator 1 | Servier BioInnovation | $470.00 | 10/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) | No dispute reported | 06/30/2026 | 1235975091 |
| Principal investigator 1 | Servier BioInnovation | $1,950.00 | 10/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) | No dispute reported | 06/30/2026 | 1235975094 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,240.00 | 10/02/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176650445 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $34,430.00 | 09/25/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417259 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $41,589.96 | 09/18/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY | A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome | No dispute reported | 06/30/2026 | 1190305197 |
| Principal investigator 1 | ABBVIE INC. | $62,472.00 | 09/15/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202510964 |
| Principal investigator 1 | ABBVIE INC. | $8,329.60 | 09/15/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202510966 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $12,616.78 | 09/04/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176647180 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $37,000.00 | 09/01/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417965 |
| Principal investigator 1 | ABBVIE INC. | $1,248.96 | 08/28/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202506517 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $17,323.44 | 08/25/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | ASTX727-07 | No dispute reported | 06/30/2026 | 1211416578 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,950.00 | 08/25/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | ASTX727-07 | No dispute reported | 06/30/2026 | 1211417963 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,008.00 | 08/25/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419373 |
| Principal investigator 1 | ABBVIE INC. | $46,854.00 | 08/14/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) | No dispute reported | 06/30/2026 | 1202504951 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,450.00 | 07/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419371 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,500.00 | 07/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418673 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $9,650.00 | 07/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211420119 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $35,924.20 | 07/22/2025 | Covered Recipient Teaching Hospital Arthur G James Cancer Hospital | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1236001829 |
| Principal investigator 1 | ABBVIE INC. | $46,854.00 | 07/17/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia | No dispute reported | 06/30/2026 | 1202498830 |
| Principal investigator 1 | ABBVIE INC. | $624.48 | 07/17/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia | No dispute reported | 06/30/2026 | 1202498832 |
| Principal investigator 1 | ABBVIE INC. | $6,247.20 | 07/17/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia | No dispute reported | 06/30/2026 | 1202498834 |
| Principal investigator 1 | Incyte Corporation | $15,594.00 | 07/15/2025 | Non-covered Recipient Entity The Ohio State University | Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML | No dispute reported | 06/30/2026 | 1240602557 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $24,100.00 | 07/01/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211420117 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,618.24 | 06/23/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415153 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $254.59 | 06/23/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | ASTX727-07 | No dispute reported | 06/30/2026 | 1211418679 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $12,000.00 | 06/18/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176636536 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,467.69 | 06/18/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176636539 |
| Principal investigator 1 | Incyte Corporation | $6,565.00 | 06/13/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib | No dispute reported | 06/30/2026 | 1240602719 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,805,351.00 | 06/12/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY | Inflammation Modification to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Signicance Trial (IMPACT) | No dispute reported | 06/30/2026 | 1190305191 |
| Principal investigator 1 | Incyte Corporation | $5,198.00 | 06/10/2025 | Non-covered Recipient Entity The Ohio State University | Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML | No dispute reported | 06/30/2026 | 1240602552 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $270.06 | 06/05/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176635995 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $81.02 | 06/05/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176635999 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $23,800.15 | 06/05/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176636003 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,962.00 | 06/05/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176636006 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 06/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186719 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 06/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186721 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 06/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186723 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 06/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186725 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $13,630.00 | 06/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418677 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 05/26/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186696 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 05/26/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186715 |
| Principal investigator 1 | Geron Corporation | $750.00 | 05/16/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | No dispute reported | 06/30/2026 | 1238895215 |
| Principal investigator 1 | ABBVIE INC. | $10,414.40 | 05/12/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets | No dispute reported | 06/30/2026 | 1202484667 |
| Principal investigator 1 | ABBVIE INC. | $8,326.40 | 05/12/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets | No dispute reported | 06/30/2026 | 1202484669 |
| Principal investigator 1 | Astellas Pharma Global Development | $260.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186682 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186684 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186686 |
| Principal investigator 1 | Astellas Pharma Global Development | $260.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186688 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186690 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186692 |
| Principal investigator 1 | Astellas Pharma Global Development | $12,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186694 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186698 |
| Principal investigator 1 | Astellas Pharma Global Development | $6,202.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186700 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186702 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186704 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186706 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186709 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186711 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186713 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,000.00 | 05/09/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186717 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186380 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186382 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186384 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186392 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186394 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186396 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186398 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186400 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186402 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186404 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186406 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186408 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186410 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186412 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186414 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186416 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186418 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186420 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186422 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186424 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186426 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186428 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186430 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186432 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186434 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186436 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,035.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186438 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186442 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186444 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186446 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186448 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 04/30/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186450 |
| Principal investigator 1 | ABBVIE INC. | $26,036.00 | 04/28/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets | No dispute reported | 06/30/2026 | 1202479797 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,400.00 | 04/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415151 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $38,820.00 | 04/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211416580 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $72,300.00 | 04/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417969 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $64,690.00 | 04/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417971 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,400.00 | 04/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418675 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $12,600.00 | 04/28/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419375 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $15,200.00 | 04/17/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415149 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,400.00 | 04/17/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417967 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,945.00 | 04/08/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (STIMULUS-MD | No dispute reported | 06/30/2026 | 1190299831 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,491.00 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186374 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,860.00 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186376 |
| Principal investigator 1 | Astellas Pharma Global Development | $6,000.00 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186378 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,076.00 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186386 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186388 |
| Principal investigator 1 | Astellas Pharma Global Development | $6,485.00 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186390 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,600.00 | 04/02/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186440 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $30,190.90 | 04/02/2025 | Non-covered Recipient Entity The Ohio State University | FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC | No dispute reported | 06/30/2026 | 1226135824 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,101.09 | 03/27/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176630843 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $54.00 | 03/27/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176630847 |
| Principal investigator 1 | Astellas Pharma Global Development | $305.76 | 03/25/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186454 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186452 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186456 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186458 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186460 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186462 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186464 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186466 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186468 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186470 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186472 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186474 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186476 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186478 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186480 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186482 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186484 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186486 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186488 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186490 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,829.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186492 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186494 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186496 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186498 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186500 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186502 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186504 |
| Principal investigator 1 | Astellas Pharma Global Development | $321.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186506 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186508 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186510 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186512 |
| Principal investigator 1 | Astellas Pharma Global Development | $321.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186514 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186516 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186518 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186520 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186522 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186524 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186526 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186528 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186530 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186532 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186534 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186536 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186538 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,829.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186540 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186542 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186544 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186546 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186548 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186550 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186552 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186554 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186556 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186558 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186560 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186562 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186564 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186566 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186568 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186570 |
| Principal investigator 1 | Astellas Pharma Global Development | $884.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186572 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186574 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186576 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186578 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186580 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186582 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186584 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186586 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186588 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186590 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186592 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186594 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186596 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186598 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186600 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186602 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,907.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186604 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186606 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186608 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186610 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186612 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186614 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186616 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186618 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186620 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186622 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186624 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,881.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186626 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186628 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186630 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186632 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186634 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186636 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186638 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186640 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186642 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186644 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186646 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186648 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186650 |
| Principal investigator 1 | Astellas Pharma Global Development | $884.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186652 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186654 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186656 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186658 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186660 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186662 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,541.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186664 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,003.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186666 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186668 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186670 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186672 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186674 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,818.00 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186676 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,281.80 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186678 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,510.60 | 03/21/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186680 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $274.00 | 03/18/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY CLINICAL TRIALS OFFICE | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176630549 |
| Principal investigator 1 | ABBVIE INC. | $10,408.00 | 03/13/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets | No dispute reported | 06/30/2026 | 1202463843 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $150.45 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $24.95 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375441 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375443 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375445 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375447 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $124.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375449 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $124.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375451 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12.75 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375453 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $150.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375455 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375457 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375459 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375463 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $69.30 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375467 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375469 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375471 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375473 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Non-covered Recipient Entity Ohio State University | AC220-168 | No dispute reported | 06/30/2026 | 1223375475 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,000.00 | 02/27/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176628625 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $28,388.03 | 02/27/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176628629 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,390.00 | 02/27/2025 | Non-covered Recipient Entity COMPREHENSIVE CANCER CENTER | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176628633 |
| Principal investigator 1 | Celgene Corporation | $67,322.58 | 02/21/2025 | Non-covered Recipient Entity Ohio State University | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222307157 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $338.00 | 02/14/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY CLINICAL TRIALS OFFICE | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | No dispute reported | 06/30/2026 | 1176627750 |
| Principal investigator 1 | ABBVIE INC. | $52,072.00 | 02/04/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets | No dispute reported | 06/30/2026 | 1202443881 |
| Principal investigator 1 | ABBVIE INC. | $62,472.00 | 01/30/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets | No dispute reported | 06/30/2026 | 1202443381 |
| Principal investigator 1 | ABBVIE INC. | $83,296.00 | 01/28/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets | No dispute reported | 06/30/2026 | 1202441747 |
| Principal investigator 1 | Astellas Pharma Global Development | $6,500.00 | 01/27/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186366 |
| Principal investigator 1 | Astellas Pharma Global Development | $650.00 | 01/24/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186368 |
| Principal investigator 1 | Astellas Pharma Global Development | $650.00 | 01/24/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186370 |
| Principal investigator 1 | Astellas Pharma Global Development | $650.00 | 01/24/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | No dispute reported | 06/30/2026 | 1234186372 |
| Principal investigator 1 | Incyte Corporation | $975.00 | 01/22/2025 | Non-covered Recipient Entity The Ohio State University | Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML | No dispute reported | 06/30/2026 | 1240602562 |
| Principal investigator 1 | Incyte Corporation | $1,197.00 | 01/22/2025 | Non-covered Recipient Entity The Ohio State University | Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML | No dispute reported | 06/30/2026 | 1240602566 |
| Principal investigator 1 | ABBVIE INC. | $83,296.00 | 01/21/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER | A20-256;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets | No dispute reported | 06/30/2026 | 1202440471 |
| Principal investigator 1 | Celgene Corporation | $122,875.95 | 01/17/2025 | Non-covered Recipient Entity Ohio State University | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222307165 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $56,702.40 | 01/07/2025 | Covered Recipient Teaching Hospital Arthur G James Cancer Hospital | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1236001827 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $35,263.35 | 01/07/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome | No dispute reported | 06/30/2026 | 1190299835 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $220.00 | 01/01/2025 | Non-covered Recipient Entity OHIO STATE UNIVERSITY | Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria | No dispute reported | 06/30/2026 | 1190305195 |